Search | Clinical Trials Finder

Conditions: Metabolic Syndrome
Interventions: Metformin, Placebo, Low Intensity Exercise, High Intensity Exercise; Drug · Behavioral
Lead sponsor: Rutgers University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas

Conditions: Breast Cancer
Interventions: Everolimus, Exemestane, Metformin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide, metformin, repaglinide and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 100 mg, Canagliflozin 300 mg, Metformin XR; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encinitas, California + 49 more

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 994 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 44
States / cities: Birmingham, Alabama • Haleyville, Alabama • Tempe, Arizona + 36 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Osteoarthritis, Knee, Post-traumatic Osteoarthritis, ACL Tear
Interventions: Metformin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Atlanta, Georgia • Iowa City, Iowa • Lexington, Kentucky + 6 more

Conditions: Peripheral Artery Disease
Interventions: Metformin 1000 mg, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Alpelisib, Fulvestrant, Metformin XR, Dapagliflozin + metformin XR, Dapagliflozin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 109
States / cities: Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more

Conditions: NIDDM, Obesity
Interventions: Metformin Extended Release (ER) Oral Tablet, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Interaction Drug Food
Interventions: goldenseal, Metformin, Furosemide, Midazolam oral solution, Rosuvastatin Oral Tablet; Dietary Supplement · Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Healthy
Interventions: Metformin Hydrochloride ER Tablets 500 mg, Glucophage XR 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Interaction, Endogenous Biomarkers
Interventions: MetFORMIN Oral Solution, Cimetidine 400 MG, Furosemide Oral Liquid Product, Probenecid 500 MG; Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 79
States / cities: Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo (Saxagliptin), Metformin IR, Placebo (Metformin), Metformin (Active Rescue); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Hollywood, Florida + 6 more

Conditions: Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Metformin, saxagliptin, AZD9668, placebo; Drug
Lead sponsor: Nick Giannoukakis, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: saxagliptin, metformin XR, saxagliptin + metformin XR (FDC tablet); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Co-administration of Saxagliptin and Metformin IR, Fasted, Saxagliptin/Metformin, Fasting, Co-administration of Saxagliptin and Metformin IR, Fed, Saxagliptin/Metformin, Fed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Diabetes Mellitus, Type 2
Interventions: Metformin DR, Metformin IR, Metformin DR Placebo, Metformin IR placebo; Drug
Lead sponsor: Anji Pharma; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 33
States / cities: Glendale, Arizona • Mesa, Arizona • Apple Valley, California + 30 more

Conditions: Healthy
Interventions: Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/500, CANA/MET XR FDC, Formulation 2, 150 mg/500 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release); Drug
Lead sponsor: Elcelyx Therapeutics, Inc.; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Search by objective public record fields.

Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Exemestane-RAD001-Metformin

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Preventing Injured Knees From osteoArthritis: Severity Outcomes

Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes

Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo

Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach

Food BE Study Metformin Hydrochloride ER Tablets 500 mg and Glucophage XR 500 mg

Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

Investigational Study of Delayed Release Metformin

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM